Product image of Maymetsi (Metformin Hydrochloride, Sitagliptin) supplied by GNH India

Maymetsi

Active Ingredient:
Metformin Hydrochloride, Sitagliptin
Origin:
EU

Maymetsi (Metformin Hydrochloride, Sitagliptin)

Metformin Hydrochloride and Sitagliptin, the active ingredient in Maymetsi, is a Biguanide / DPP-4 inhibitor presented as an oral tablet for oral use. It is indicated for the management of type 2 diabetes mellitus in adult patients, helping to control blood glucose levels when used in combination with diet and exercise.

GNH India supplies Maymetsi as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, ensuring quality and regulatory compliance across markets and providing reliable distribution.

Manufacturer / TM Owner

Krka, D.D., Novo Mesto

1
Pack/s
This product is added to your enquiry list

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

A minimum order value applies. Our team will confirm the exact amount or quantity after reviewing your requirements.

Indications & Clinical Uses

Maymetsi combines metformin and sitagliptin to treat disorders of glucose metabolism, primarily type 2 diabetes mellitus.

  • Type 2 diabetes mellitus: lowers fasting and post‑prandial glucose levels to improve overall glycaemic control.
  • Adjunct to lifestyle modification: enhances the effect of diet and exercise on blood sugar regulation.
  • Inadequate control on metformin alone: provides additional DPP‑4 inhibition for patients needing further glucose reduction.

How It Works

  • Metformin decreases hepatic gluconeogenesis and improves peripheral insulin sensitivity, while sitagliptin inhibits the enzyme dipeptidyl peptidase‑4 (DPP‑4), leading to increased endogenous incretin levels that stimulate glucose‑dependent insulin secretion and suppress glucagon release, together producing a complementary reduction in blood glucose.

Side Effects

Adverse reactions may occur with any antidiabetic therapy and should be monitored.

Common Side Effects

  • Gastrointestinal upset: nausea, abdominal discomfort, or diarrhea.
  • Headache: mild to moderate intensity.
  • Hypoglycaemia: especially when combined with other glucose‑lowering agents.
  • Metallic taste: transient alteration in taste perception.

Serious or Rare Side Effects

  • Lactic acidosis: a rare but life‑threatening metabolic complication.
  • Pancreatitis: severe abdominal pain with elevated enzymes.
  • Severe allergic reactions: rash, angioedema, or anaphylaxis.
  • Hepatic failure: signs of liver dysfunction.
  • Renal impairment worsening: especially in patients with pre‑existing kidney disease.

Precautions & Warnings

Before prescribing Maymetsi, clinicians should consider several safety factors.

  • Renal function: assess baseline creatinine clearance and monitor regularly.
  • Hepatic impairment: use with caution in patients with liver disease.
  • Risk of lactic acidosis: avoid in patients with significant hypoxia, severe renal dysfunction, or alcohol abuse.
  • Pregnancy and lactation: safety not established; consider alternative therapy.
  • Drug interactions: review concomitant medicines for additive hypoglycaemia risk.
  • Store at ambient temperature: keep below 25°C in the original pack, protect from moisture.

Avoid Interactions

Maymetsi may interact with several drug classes, requiring attention to avoid adverse outcomes.

Major Interactions (Avoid)

  • Phenformin or other contraindicated biguanides: increased risk of lactic acidosis.
  • Strong CYP3A4 inhibitors (e.g., ketoconazole): may raise sitagliptin plasma levels.
  • Iodinated IV contrast agents: can impair renal function, necessitating temporary metformin discontinuation.

Moderate Interactions (Monitor Closely)

  • Sulfonylureas: heightened risk of hypoglycaemia.
  • Diuretics (especially thiazides): may affect renal clearance of metformin.
  • ACE inhibitors or ARBs: monitor renal function and electrolytes during combined use.

Frequently Asked Questions

Maymetsi is prescribed to adults with type 2 diabetes mellitus to improve blood glucose control. It combines metformin, which reduces liver glucose production, with sitagliptin, which enhances insulin secretion in response to meals, providing a complementary approach to managing hyperglycaemia.

Metformin Hydrochloride lowers blood sugar primarily by inhibiting hepatic gluconeogenesis, decreasing the amount of glucose released by the liver. It also improves peripheral insulin sensitivity, allowing muscle and fat cells to take up glucose more efficiently.

The appropriate dose of Maymetsi is determined by the prescribing clinician based on the patient’s individual clinical profile, renal function, and response to therapy. Dosage adjustments are made to achieve optimal glycaemic control while minimizing adverse effects.

Safety data for Maymetsi in pregnancy and lactation are limited. Because metformin crosses the placenta and sitagliptin’s effects on the fetus are not fully established, clinicians usually consider alternative treatments for pregnant or nursing women.

To request Maymetsi, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Maymetsi offers a fixed‑dose combination of metformin and sitagliptin, providing both insulin‑sensitising and incretin‑based mechanisms. Compared with metformin alone, it delivers greater HbA1c reduction, and versus sitagliptin monotherapy it adds the glucose‑lowering effect of metformin, often reducing the need for additional agents.

Maymetsi tablets should be stored at ambient temperature, preferably below 25 °C. Keep the product in its original packaging, protect it from moisture and direct sunlight, and ensure the container is tightly closed to maintain stability.

Maymetsi is taken orally, usually with meals to reduce gastrointestinal discomfort. The tablet is swallowed whole with a full glass of water. Patients should follow the dosing schedule prescribed by their healthcare professional.

The most serious risks include lactic acidosis, a rare but potentially fatal condition linked to metformin, and pancreatitis, which can occur with sitagliptin. Patients should seek immediate medical attention for symptoms such as severe abdominal pain, rapid breathing, or unexplained fatigue.

Maymetsi is contraindicated in patients with severe renal impairment (eGFR < 30 mL/min/1.73 m²), known hypersensitivity to metformin or sitagliptin, acute or chronic metabolic acidosis, and those receiving phenformin. Caution is also advised for individuals with significant hepatic disease.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated:

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.

Related Products

Other formulations containing Metformin Hydrochloride, Sitagliptin

A

A
A

A
A

A
A

A

Browse all products →

Ordering Process

Simple, Secure, and Seamless

Learn how our streamlined ordering process guarantees fast, compliant, and reliable access to essential medicines worldwide.

Quote request form

01

Submit Quote Request Form

Tell us what medications you need by filling out our simple form and uploading a valid document.

Price estimate review

02

We Review & Send Estimate

Our licensed pharmacists will verify your details and provide you with a detailed cost estimate.

Secure payment

03

Confirm & Make Payment

Discuss any queries, approve the estimate, and complete your payment.

Worldwide delivery

04

Get Delivered

Your medicines, safely packed and delivered to your door or nearest airport — hassle-free.

Regulatory recognitions

Quality You Can Trust

Our internationally recognized certifications underscore our commitment to safety, quality, and excellence.

SGS GSDP Certification

GSDP Compliant from SGS

URS ISO 9001

URS ISO 9001 Certification

FDA Maharashtra

Licensed by FDA Maharashtra

IEC License DGFT

IEC License issued by DGFT